By Katherine Hamilton
Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance.
The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low.
Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels.
While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said.
The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 20, 2024 14:44 ET (19:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。